 | • レポートコード：QYR2104Z0992 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、乳がん用モノクローナル抗体のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ネイキッドMAb、コンジュゲートMAb）、用途別市場規模（病院、小売薬局、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・乳がん用モノクローナル抗体の市場動向 ・企業の競争状況、市場シェア ・乳がん用モノクローナル抗体の種類別市場規模（ネイキッドMAb、コンジュゲートMAb） ・乳がん用モノクローナル抗体の用途別市場規模（病院、小売薬局、その他） ・乳がん用モノクローナル抗体の北米市場規模2016-2027（アメリカ、カナダ） ・乳がん用モノクローナル抗体のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・乳がん用モノクローナル抗体のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・乳がん用モノクローナル抗体の中南米市場規模2016-2027（メキシコ、ブラジル） ・乳がん用モノクローナル抗体の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Amgen、Roche、Mylan、Array BioPharma、Biocad、Boehringer Ingelheim、Bristol-Myers Squibb、Celldex Therapeutics、Celltrion、Daiichi Sankyo、GlaxoSmithKline、Immunomedics、MacroGenics、Merck、Novartis、Oncothyreon、Pfizer、Puma Biotechnology、Seattle Genetics、Sun Pharmaceutical Industries、Synta Pharmaceuticals、Teva Pharmaceuticals） ・結論 |
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.
The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs),including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.
Market Analysis and Insights: Global Breast Cancer Monoclonal Antibodies Market
The global Breast Cancer Monoclonal Antibodies market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Breast Cancer Monoclonal Antibodies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Breast Cancer Monoclonal Antibodies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Breast Cancer Monoclonal Antibodies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Breast Cancer Monoclonal Antibodies market.
Global Breast Cancer Monoclonal Antibodies Scope and Market Size
Breast Cancer Monoclonal Antibodies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Breast Cancer Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Naked MAbs
Conjugated MAbs
Segment by Application
Hospitals
Retail Pharmacies
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Amgen
Roche
Mylan
Array BioPharma
Biocad
Boehringer Ingelheim
Bristol-Myers Squibb
Celldex Therapeutics
Celltrion
Array BioPharma
Biocad
Immunomedics
MacroGenics
Merck
Novartis
Oncothyreon
Pfizer
Puma Biotechnology
Seattle Genetics
Sun Pharmaceutical Industries
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Breast Cancer Monoclonal Antibodies Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Naked MAbs
1.2.3 Conjugated MAbs
1.3 Market by Application
1.3.1 Global Breast Cancer Monoclonal Antibodies Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Retail Pharmacies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Breast Cancer Monoclonal Antibodies Market Perspective (2016-2027)
2.2 Breast Cancer Monoclonal Antibodies Growth Trends by Regions
2.2.1 Breast Cancer Monoclonal Antibodies Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Breast Cancer Monoclonal Antibodies Historic Market Share by Regions (2016-2021)
2.2.3 Breast Cancer Monoclonal Antibodies Forecasted Market Size by Regions (2022-2027)
2.3 Breast Cancer Monoclonal Antibodies Industry Dynamic
2.3.1 Breast Cancer Monoclonal Antibodies Market Trends
2.3.2 Breast Cancer Monoclonal Antibodies Market Drivers
2.3.3 Breast Cancer Monoclonal Antibodies Market Challenges
2.3.4 Breast Cancer Monoclonal Antibodies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Breast Cancer Monoclonal Antibodies Players by Revenue
3.1.1 Global Top Breast Cancer Monoclonal Antibodies Players by Revenue (2016-2021)
3.1.2 Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Players (2016-2021)
3.2 Global Breast Cancer Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Breast Cancer Monoclonal Antibodies Revenue
3.4 Global Breast Cancer Monoclonal Antibodies Market Concentration Ratio
3.4.1 Global Breast Cancer Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Breast Cancer Monoclonal Antibodies Revenue in 2020
3.5 Breast Cancer Monoclonal Antibodies Key Players Head office and Area Served
3.6 Key Players Breast Cancer Monoclonal Antibodies Product Solution and Service
3.7 Date of Enter into Breast Cancer Monoclonal Antibodies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Breast Cancer Monoclonal Antibodies Breakdown Data by Type
4.1 Global Breast Cancer Monoclonal Antibodies Historic Market Size by Type (2016-2021)
4.2 Global Breast Cancer Monoclonal Antibodies Forecasted Market Size by Type (2022-2027)
5 Breast Cancer Monoclonal Antibodies Breakdown Data by Application
5.1 Global Breast Cancer Monoclonal Antibodies Historic Market Size by Application (2016-2021)
5.2 Global Breast Cancer Monoclonal Antibodies Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Breast Cancer Monoclonal Antibodies Market Size (2016-2027)
6.2 North America Breast Cancer Monoclonal Antibodies Market Size by Type
6.2.1 North America Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021)
6.2.2 North America Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027)
6.2.3 North America Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2027)
6.3 North America Breast Cancer Monoclonal Antibodies Market Size by Application
6.3.1 North America Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021)
6.3.2 North America Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027)
6.3.3 North America Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2027)
6.4 North America Breast Cancer Monoclonal Antibodies Market Size by Country
6.4.1 North America Breast Cancer Monoclonal Antibodies Market Size by Country (2016-2021)
6.4.2 North America Breast Cancer Monoclonal Antibodies Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Breast Cancer Monoclonal Antibodies Market Size (2016-2027)
7.2 Europe Breast Cancer Monoclonal Antibodies Market Size by Type
7.2.1 Europe Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021)
7.2.2 Europe Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027)
7.2.3 Europe Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2027)
7.3 Europe Breast Cancer Monoclonal Antibodies Market Size by Application
7.3.1 Europe Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021)
7.3.2 Europe Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027)
7.3.3 Europe Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2027)
7.4 Europe Breast Cancer Monoclonal Antibodies Market Size by Country
7.4.1 Europe Breast Cancer Monoclonal Antibodies Market Size by Country (2016-2021)
7.4.2 Europe Breast Cancer Monoclonal Antibodies Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size (2016-2027)
8.2 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Type
8.2.1 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2027)
8.3 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Application
8.3.1 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2027)
8.4 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Region
8.4.1 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Breast Cancer Monoclonal Antibodies Market Size (2016-2027)
9.2 Latin America Breast Cancer Monoclonal Antibodies Market Size by Type
9.2.1 Latin America Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021)
9.2.2 Latin America Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027)
9.2.3 Latin America Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2027)
9.3 Latin America Breast Cancer Monoclonal Antibodies Market Size by Application
9.3.1 Latin America Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021)
9.3.2 Latin America Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027)
9.3.3 Latin America Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2027)
9.4 Latin America Breast Cancer Monoclonal Antibodies Market Size by Country
9.4.1 Latin America Breast Cancer Monoclonal Antibodies Market Size by Country (2016-2021)
9.4.2 Latin America Breast Cancer Monoclonal Antibodies Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size (2016-2027)
10.2 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Type
10.2.1 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2027)
10.3 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Application
10.3.1 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2027)
10.4 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Country
10.4.1 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Breast Cancer Monoclonal Antibodies Introduction
11.1.4 Amgen Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.1.5 Amgen Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Breast Cancer Monoclonal Antibodies Introduction
11.2.4 Roche Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Mylan
11.3.1 Mylan Company Details
11.3.2 Mylan Business Overview
11.3.3 Mylan Breast Cancer Monoclonal Antibodies Introduction
11.3.4 Mylan Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.3.5 Mylan Recent Development
11.4 Array BioPharma
11.4.1 Array BioPharma Company Details
11.4.2 Array BioPharma Business Overview
11.4.3 Array BioPharma Breast Cancer Monoclonal Antibodies Introduction
11.4.4 Array BioPharma Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.4.5 Array BioPharma Recent Development
11.5 Biocad
11.5.1 Biocad Company Details
11.5.2 Biocad Business Overview
11.5.3 Biocad Breast Cancer Monoclonal Antibodies Introduction
11.5.4 Biocad Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.5.5 Biocad Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Breast Cancer Monoclonal Antibodies Introduction
11.6.4 Boehringer Ingelheim Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Details
11.7.2 Bristol-Myers Squibb Business Overview
11.7.3 Bristol-Myers Squibb Breast Cancer Monoclonal Antibodies Introduction
11.7.4 Bristol-Myers Squibb Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Celldex Therapeutics
11.8.1 Celldex Therapeutics Company Details
11.8.2 Celldex Therapeutics Business Overview
11.8.3 Celldex Therapeutics Breast Cancer Monoclonal Antibodies Introduction
11.8.4 Celldex Therapeutics Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.8.5 Celldex Therapeutics Recent Development
11.9 Celltrion
11.9.1 Celltrion Company Details
11.9.2 Celltrion Business Overview
11.9.3 Celltrion Breast Cancer Monoclonal Antibodies Introduction
11.9.4 Celltrion Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.9.5 Celltrion Recent Development
11.10 Daiichi Sankyo
11.10.1 Daiichi Sankyo Company Details
11.10.2 Daiichi Sankyo Business Overview
11.10.3 Daiichi Sankyo Breast Cancer Monoclonal Antibodies Introduction
11.10.4 Daiichi Sankyo Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.10.5 Daiichi Sankyo Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Breast Cancer Monoclonal Antibodies Introduction
11.11.4 GlaxoSmithKline Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.11.5 GlaxoSmithKline Recent Development
11.12 Immunomedics
11.12.1 Immunomedics Company Details
11.12.2 Immunomedics Business Overview
11.12.3 Immunomedics Breast Cancer Monoclonal Antibodies Introduction
11.12.4 Immunomedics Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.12.5 Immunomedics Recent Development
11.13 MacroGenics
11.13.1 MacroGenics Company Details
11.13.2 MacroGenics Business Overview
11.13.3 MacroGenics Breast Cancer Monoclonal Antibodies Introduction
11.13.4 MacroGenics Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.13.5 MacroGenics Recent Development
11.14 Merck
11.14.1 Merck Company Details
11.14.2 Merck Business Overview
11.14.3 Merck Breast Cancer Monoclonal Antibodies Introduction
11.14.4 Merck Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.14.5 Merck Recent Development
11.15 Novartis
11.15.1 Novartis Company Details
11.15.2 Novartis Business Overview
11.15.3 Novartis Breast Cancer Monoclonal Antibodies Introduction
11.15.4 Novartis Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.15.5 Novartis Recent Development
11.16 Oncothyreon
11.16.1 Oncothyreon Company Details
11.16.2 Oncothyreon Business Overview
11.16.3 Oncothyreon Breast Cancer Monoclonal Antibodies Introduction
11.16.4 Oncothyreon Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.16.5 Oncothyreon Recent Development
11.17 Pfizer
11.17.1 Pfizer Company Details
11.17.2 Pfizer Business Overview
11.17.3 Pfizer Breast Cancer Monoclonal Antibodies Introduction
11.17.4 Pfizer Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.17.5 Pfizer Recent Development
11.18 Puma Biotechnology
11.18.1 Puma Biotechnology Company Details
11.18.2 Puma Biotechnology Business Overview
11.18.3 Puma Biotechnology Breast Cancer Monoclonal Antibodies Introduction
11.18.4 Puma Biotechnology Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.18.5 Puma Biotechnology Recent Development
11.18 Seattle Genetics
.1 Seattle Genetics Company Details
.2 Seattle Genetics Business Overview
.3 Seattle Genetics Breast Cancer Monoclonal Antibodies Introduction
.4 Seattle Genetics Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
.5 Seattle Genetics Recent Development
11.20 Sun Pharmaceutical Industries
11.20.1 Sun Pharmaceutical Industries Company Details
11.20.2 Sun Pharmaceutical Industries Business Overview
11.20.3 Sun Pharmaceutical Industries Breast Cancer Monoclonal Antibodies Introduction
11.20.4 Sun Pharmaceutical Industries Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.20.5 Sun Pharmaceutical Industries Recent Development
11.21 Synta Pharmaceuticals
11.21.1 Synta Pharmaceuticals Company Details
11.21.2 Synta Pharmaceuticals Business Overview
11.21.3 Synta Pharmaceuticals Breast Cancer Monoclonal Antibodies Introduction
11.21.4 Synta Pharmaceuticals Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.21.5 Synta Pharmaceuticals Recent Development
11.22 Teva Pharmaceuticals
11.22.1 Teva Pharmaceuticals Company Details
11.22.2 Teva Pharmaceuticals Business Overview
11.22.3 Teva Pharmaceuticals Breast Cancer Monoclonal Antibodies Introduction
11.22.4 Teva Pharmaceuticals Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021)
11.22.5 Teva Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Breast Cancer Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Naked MAbs
Table 3. Key Players of Conjugated MAbs
Table 4. Global Breast Cancer Monoclonal Antibodies Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Breast Cancer Monoclonal Antibodies Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Breast Cancer Monoclonal Antibodies Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Breast Cancer Monoclonal Antibodies Market Share by Regions (2016-2021)
Table 8. Global Breast Cancer Monoclonal Antibodies Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Breast Cancer Monoclonal Antibodies Market Share by Regions (2022-2027)
Table 10. Breast Cancer Monoclonal Antibodies Market Trends
Table 11. Breast Cancer Monoclonal Antibodies Market Drivers
Table 12. Breast Cancer Monoclonal Antibodies Market Challenges
Table 13. Breast Cancer Monoclonal Antibodies Market Restraints
Table 14. Global Breast Cancer Monoclonal Antibodies Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Breast Cancer Monoclonal Antibodies Market Share by Players (2016-2021)
Table 16. Global Top Breast Cancer Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Breast Cancer Monoclonal Antibodies as of 2020)
Table 17. Ranking of Global Top Breast Cancer Monoclonal Antibodies Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Breast Cancer Monoclonal Antibodies Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Breast Cancer Monoclonal Antibodies Product Solution and Service
Table 21. Date of Enter into Breast Cancer Monoclonal Antibodies Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Type (2016-2021)
Table 25. Global Breast Cancer Monoclonal Antibodies Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Breast Cancer Monoclonal Antibodies Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Application (2016-2021)
Table 29. Global Breast Cancer Monoclonal Antibodies Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Breast Cancer Monoclonal Antibodies Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Breast Cancer Monoclonal Antibodies Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Breast Cancer Monoclonal Antibodies Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Breast Cancer Monoclonal Antibodies Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Breast Cancer Monoclonal Antibodies Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Breast Cancer Monoclonal Antibodies Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size by Country (2022-2027) & (US$ Million)
Table 61. Amgen Company Details
Table 62. Amgen Business Overview
Table 63. Amgen Breast Cancer Monoclonal Antibodies Product
Table 64. Amgen Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 65. Amgen Recent Development
Table 66. Roche Company Details
Table 67. Roche Business Overview
Table 68. Roche Breast Cancer Monoclonal Antibodies Product
Table 69. Roche Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 70. Roche Recent Development
Table 71. Mylan Company Details
Table 72. Mylan Business Overview
Table 73. Mylan Breast Cancer Monoclonal Antibodies Product
Table 74. Mylan Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 75. Mylan Recent Development
Table 76. Array BioPharma Company Details
Table 77. Array BioPharma Business Overview
Table 78. Array BioPharma Breast Cancer Monoclonal Antibodies Product
Table 79. Array BioPharma Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 80. Array BioPharma Recent Development
Table 81. Biocad Company Details
Table 82. Biocad Business Overview
Table 83. Biocad Breast Cancer Monoclonal Antibodies Product
Table 84. Biocad Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 85. Biocad Recent Development
Table 86. Boehringer Ingelheim Company Details
Table 87. Boehringer Ingelheim Business Overview
Table 88. Boehringer Ingelheim Breast Cancer Monoclonal Antibodies Product
Table 89. Boehringer Ingelheim Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 90. Boehringer Ingelheim Recent Development
Table 91. Bristol-Myers Squibb Company Details
Table 92. Bristol-Myers Squibb Business Overview
Table 93. Bristol-Myers Squibb Breast Cancer Monoclonal Antibodies Product
Table 94. Bristol-Myers Squibb Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 95. Bristol-Myers Squibb Recent Development
Table 96. Celldex Therapeutics Company Details
Table 97. Celldex Therapeutics Business Overview
Table 98. Celldex Therapeutics Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 99. Celldex Therapeutics Recent Development
Table 100. Celltrion Company Details
Table 101. Celltrion Business Overview
Table 102. Celltrion Breast Cancer Monoclonal Antibodies Product
Table 103. Celltrion Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 104. Celltrion Recent Development
Table 105. Daiichi Sankyo Company Details
Table 106. Daiichi Sankyo Business Overview
Table 107. Daiichi Sankyo Breast Cancer Monoclonal Antibodies Product
Table 108. Daiichi Sankyo Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 109. Daiichi Sankyo Recent Development
Table 110. GlaxoSmithKline Company Details
Table 111. GlaxoSmithKline Business Overview
Table 112. GlaxoSmithKline Breast Cancer Monoclonal Antibodies Product
Table 113. GlaxoSmithKline Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 114. GlaxoSmithKline Recent Development
Table 115. Immunomedics Company Details
Table 116. Immunomedics Business Overview
Table 117. Immunomedics Breast Cancer Monoclonal Antibodies Product
Table 118. Immunomedics Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 119. Immunomedics Recent Development
Table 120. MacroGenics Company Details
Table 121. MacroGenics Business Overview
Table 122. MacroGenics Breast Cancer Monoclonal Antibodies Product
Table 123. MacroGenics Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 124. MacroGenics Recent Development
Table 125. Merck Company Details
Table 126. Merck Business Overview
Table 127. Merck Breast Cancer Monoclonal Antibodies Product
Table 128. Merck Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 129. Merck Recent Development
Table 130. Novartis Company Details
Table 131. Novartis Business Overview
Table 132. Novartis Breast Cancer Monoclonal Antibodies Product
Table 133. Novartis Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 134. Novartis Recent Development
Table 135. Oncothyreon Company Details
Table 136. Oncothyreon Business Overview
Table 137. Oncothyreon Breast Cancer Monoclonal Antibodies Product
Table 138. Oncothyreon Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 139. Oncothyreon Recent Development
Table 140. Pfizer Company Details
Table 141. Pfizer Business Overview
Table 142. Pfizer Breast Cancer Monoclonal Antibodies Product
Table 143. Pfizer Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 144. Pfizer Recent Development
Table 145. Puma Biotechnology Company Details
Table 146. Puma Biotechnology Business Overview
Table 147. Puma Biotechnology Breast Cancer Monoclonal Antibodies Product
Table 148. Puma Biotechnology Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 149. Puma Biotechnology Recent Development
Table 150. Seattle Genetics Company Details
Table 151. Seattle Genetics Business Overview
Table 152. Seattle Genetics Breast Cancer Monoclonal Antibodies Product
Table 153. Seattle Genetics Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 154. Seattle Genetics Recent Development
Table 155. Sun Pharmaceutical Industries Company Details
Table 156. Sun Pharmaceutical Industries Business Overview
Table 157. Sun Pharmaceutical Industries Breast Cancer Monoclonal Antibodies Product
Table 158. Sun Pharmaceutical Industries Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 159. Sun Pharmaceutical Industries Recent Development
Table 160. Synta Pharmaceuticals Company Details
Table 161. Synta Pharmaceuticals Business Overview
Table 162. Synta Pharmaceuticals Breast Cancer Monoclonal Antibodies Product
Table 163. Synta Pharmaceuticals Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 164. Synta Pharmaceuticals Recent Development
Table 165. Teva Pharmaceuticals Company Details
Table 166. Teva Pharmaceuticals Business Overview
Table 167. Teva Pharmaceuticals Breast Cancer Monoclonal Antibodies Product
Table 168. Teva Pharmaceuticals Revenue in Breast Cancer Monoclonal Antibodies Business (2016-2021) & (US$ Million)
Table 169. Teva Pharmaceuticals Recent Development
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Breast Cancer Monoclonal Antibodies Market Share by Type: 2020 VS 2027
Figure 2. Naked MAbs Features
Figure 3. Conjugated MAbs Features
Figure 4. Global Breast Cancer Monoclonal Antibodies Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Retail Pharmacies Case Studies
Figure 7. Others Case Studies
Figure 8. Breast Cancer Monoclonal Antibodies Report Years Considered
Figure 9. Global Breast Cancer Monoclonal Antibodies Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Breast Cancer Monoclonal Antibodies Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Breast Cancer Monoclonal Antibodies Market Share by Regions: 2020 VS 2027
Figure 12. Global Breast Cancer Monoclonal Antibodies Market Share by Regions (2022-2027)
Figure 13. Global Breast Cancer Monoclonal Antibodies Market Share by Players in 2020
Figure 14. Global Top Breast Cancer Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Breast Cancer Monoclonal Antibodies as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Breast Cancer Monoclonal Antibodies Revenue in 2020
Figure 16. Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Type (2016-2021)
Figure 17. Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Type (2022-2027)
Figure 18. North America Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Breast Cancer Monoclonal Antibodies Market Share by Type (2016-2027)
Figure 20. North America Breast Cancer Monoclonal Antibodies Market Share by Application (2016-2027)
Figure 21. North America Breast Cancer Monoclonal Antibodies Market Share by Country (2016-2027)
Figure 22. United States Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Breast Cancer Monoclonal Antibodies Market Share by Type (2016-2027)
Figure 26. Europe Breast Cancer Monoclonal Antibodies Market Share by Application (2016-2027)
Figure 27. Europe Breast Cancer Monoclonal Antibodies Market Share by Country (2016-2027)
Figure 28. Germany Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Share by Region (2016-2027)
Figure 38. China Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Breast Cancer Monoclonal Antibodies Market Share by Type (2016-2027)
Figure 46. Latin America Breast Cancer Monoclonal Antibodies Market Share by Application (2016-2027)
Figure 47. Latin America Breast Cancer Monoclonal Antibodies Market Share by Country (2016-2027)
Figure 48. Mexico Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Breast Cancer Monoclonal Antibodies Market Share by Country (2016-2027)
Figure 54. Turkey Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Amgen Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 58. Roche Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 59. Mylan Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 60. Array BioPharma Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 61. Biocad Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 62. Boehringer Ingelheim Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 64. Celldex Therapeutics Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 65. Celltrion Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 66. Daiichi Sankyo Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 67. GlaxoSmithKline Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 68. Immunomedics Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 69. MacroGenics Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 70. Merck Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 71. Novartis Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 72. Oncothyreon Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 73. Pfizer Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 74. Puma Biotechnology Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 75. Seattle Genetics Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 76. Sun Pharmaceutical Industries Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 77. Synta Pharmaceuticals Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 78. Teva Pharmaceuticals Revenue Growth Rate in Breast Cancer Monoclonal Antibodies Business (2016-2021)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
世界のCD38モノクローナル抗体市場規模・現状・予測（2021年-2027年） CD38 monoclonal antibodies target the CD38 surface antigen(sAg) of hematopoietic cells, which is important for cell function. Once CD38 monoclonal antibodies bind to the antigen it inhibits tumour growth by interrupting CD38 functions and causes cell death. CD38 monoclonal antibodies are used to tre…- 世界のトリプルネガティブ乳がん治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Triple-Negative Breast Cancer Treatment Market The global Triple-Negative Breast Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis…
- 世界の乳がん用画像市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Breast Cancer Imaging Market The global Breast Cancer Imaging market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report…
- 世界の乳がん治療市場規模・現状・予測（2021年-2027年） Breast cancer is the one of the most prevalent cancer and among the leading cause of death in cancer patients. According, to WHO 2013 report 50800 women died of breast cancer in 2011. Metastatic breast cancer is an advanced stage of breast cancer. It involves cases in which breast cancer has spread …
- 世界の乳がん治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Breast Cancer Therapeutic Market The global Breast Cancer Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, th…